SCHEDULE: Woodline Partners Discloses 8.7% Stake in Aligos Therapeutics
Schedule 13G Amendment
Woodline Partners LP has filed an amended Schedule 13G, reporting an 8.7% beneficial ownership of Aligos Therapeutics, Inc.'s common stock as of September 30, 2025.
Summary
- Woodline Partners LP, a Delaware limited partnership and investment adviser, has disclosed a beneficial ownership of 468,199 shares of Voting Common Stock in Aligos Therapeutics, Inc.
- This stake represents 8.7% of Aligos Therapeutics' outstanding common stock.
- The percentage is calculated based on 5,351,374 shares of Voting Common Stock outstanding as of July 31, 2025, as reported in Aligos Therapeutics' Form 10-Q filed on August 6, 2025.
- Woodline Partners LP holds sole voting power and sole dispositive power over all 468,199 shares.
- The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of Aligos Therapeutics, Inc.
Sentiment
Score: 5
Explanation: The filing is a standard disclosure of beneficial ownership by an institutional investor, indicating a passive stake. It does not contain information that would significantly alter the sentiment positively or negatively regarding the company's operational performance or future prospects.
Positives
- The disclosure of an 8.7% stake by an institutional investor like Woodline Partners LP may signal institutional confidence in Aligos Therapeutics, Inc.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders of Aligos Therapeutics, Inc. gain transparency regarding the significant institutional ownership by Woodline Partners LP.
Key Dates
| Date | Description |
|---|---|
| 07/31/2025 | Date as of which 5,351,374 shares of Voting Common Stock were outstanding, used for percentage calculation. |
| 08/06/2025 | Date Aligos Therapeutics, Inc. filed its Quarterly Report on Form 10-Q for the period ended June 30, 2025. |
| 09/30/2025 | Date of event which requires the filing of this statement. |
| 11/14/2025 | Date the Schedule 13G Amendment No. 2 was signed by Woodline Partners LP. |
Keywords
Aligos Therapeutics, Woodline Partners, Schedule 13G, beneficial ownership, institutional investor, common stock, biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.